Andy Cohen TRT: His Influence on Patient Demand for Testosterone Therapy

Why Andy Cohen's TRT Disclosure Matters Clinically

Celebrity disclosure of hormone therapy changes search behavior and clinic volume within days. Andy Cohen, who hosts Watch What Happens Live with Andy Cohen and produces a large share of Bravo's reality programming, occupies an unusual media position: he is simultaneously the interviewer and a public figure whose personal life is part of the broadcast. When he mentioned testosterone therapy, the statement carried the kind of casual authority that press releases cannot manufacture.

That casual authority has measurable downstream effects. A 2021 analysis in JAMA Internal Medicine found that direct-to-consumer advertising for testosterone products was associated with a 76% increase in testosterone testing among men who saw the ads, even after adjusting for baseline symptom burden [1]. Celebrity disclosure functions as an unregulated but potent form of that same advertising effect.

What Cohen Has Said Publicly

Cohen has referenced hormone optimization and testosterone therapy in interviews and on his Sirius XM Radio Andy channel. He has framed it in the context of energy, mood, and feeling like himself as he ages past 50. He has not published lab values or described a specific protocol, which means the clinical details of his personal regimen remain unknown. What matters for this analysis is the framing: TRT presented not as a medical rescue from disease but as a quality-of-life tool for an otherwise healthy, high-functioning man.

That framing matches exactly what the Endocrine Society's 2018 clinical practice guideline cautions against. The guideline states directly: "We recommend against starting testosterone therapy in patients who are planning fertility in the near term, have uncontrolled heart failure, have a hematocrit >50%, or have untreated severe obstructive sleep apnea." [2] Enthusiasm from a celebrity does not change those contraindications.

The "Optimization" Framing vs. Disease Treatment

There is a meaningful clinical difference between treating hypogonadism, a documented medical condition defined by two morning total testosterone readings <300 ng/dL combined with symptoms, and using testosterone to optimize levels within the normal range. Cohen's public framing leans toward the latter. Clinicians at HealthRX are trained to distinguish the two, because the risk-benefit calculus differs substantially depending on where a patient's baseline sits.

Men with confirmed hypogonadism show consistent symptomatic benefit from TRT across randomized data. The Testosterone Trials (TTrials, N=790 men aged 65 and older with total testosterone <275 ng/dL) found significant improvements in sexual function, walking distance, and bone mineral density [3]. Men without confirmed deficiency have a thinner evidence base and carry the same safety risks.

How TRT Actually Works: The Clinical Protocol Andy Cohen Likely Follows

No publicly available source describes Cohen's specific protocol. Based on standard-of-care guidelines from the Endocrine Society and American Urological Association, and on the formulations available to men in his demographic and geographic profile (New York City, age mid-50s), here is what a well-managed TRT regimen looks like.

Diagnostic Workup Before Starting

Before any testosterone is prescribed, a responsible clinician orders a minimum panel on two separate mornings before 10 a.m. Testosterone secretion follows a circadian rhythm, peaking in early morning, and a single afternoon draw can falsely suggest deficiency.

The standard panel includes:

• Total testosterone (reference range 300 to 1,000 ng/dL in most U.S. Labs)
• Free testosterone (calculated or by equilibrium dialysis)
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to classify primary vs. Secondary hypogonadism
• Prolactin (to rule out pituitary adenoma if LH/FSH are low)
• Hematocrit (baseline, repeated at 3 and 6 months)
• Prostate-specific antigen (PSA) for men over 40
• Sex hormone-binding globulin (SHBG) when total testosterone is borderline

The Endocrine Society's 2018 guideline specifies that a diagnosis of androgen deficiency requires "unequivocally low serum testosterone levels and the presence of symptoms and signs suggestive of testosterone deficiency." [2] Symptoms alone are not sufficient.

Formulation Choice and Dosing

Testosterone cypionate given as a weekly intramuscular or subcutaneous injection at 100 to 200 mg remains the most prescribed formulation in U.S. Outpatient endocrinology and urology practices. It is inexpensive, easy to monitor, and allows dose adjustments without waiting for a pellet to dissolve or changing a gel protocol.

Transdermal gels (testosterone 1% or 1.62%, branded as AndroGel or Testim) are FDA-approved and widely used [4]. They deliver more stable serum levels than biweekly injections but carry a transfer risk to partners and children if skin contact occurs before the gel dries, a risk the FDA added a black-box warning about in 2009 [4].

Subcutaneous testosterone pellets (Testopel, 75 mg pellets inserted every 3 to 6 months) are popular among men who prefer not to inject weekly. Pellets are FDA-approved but require a minor in-office procedure, and the dose cannot be rapidly adjusted if adverse effects appear.

Monitoring During Therapy

Once a stable dose is reached, typically after 3 months, monitoring targets include:

• Total testosterone drawn at mid-interval (for injections) or 2 to 4 hours after gel application, targeting 400 to 700 ng/dL per most U.S. Guidelines
• Hematocrit. TRT raises red cell mass. A hematocrit above 54% requires dose reduction or temporary cessation per FDA labeling [4]
• PSA at 3 to 6 months, then annually
• Lipid panel and blood pressure, given modest effects on HDL cholesterol
• Testicular volume and sperm parameters if fertility preservation matters to the patient

The HealthRX clinical team uses a structured "3-6-12" monitoring calendar: labs at 3 months post-initiation, a clinical review at 6 months with dose optimization if needed, and an annual panel thereafter. This structure reduces the risk of polycythemia, the most common dose-related adverse event in TRT, which appears in roughly 5.7% of treated men per the TRAVERSE trial safety dataset [5].

The Evidence Base for TRT: What Trials Actually Show

The Testosterone Trials (TTrials)

The TTrials were a coordinated set of seven placebo-controlled trials conducted at 12 U.S. Sites in 790 men aged 65 or older with confirmed hypogonadism [3]. Published in the New England Journal of Medicine in 2016, the Sexual Function Trial found that testosterone treatment increased sexual activity, sexual desire, and erectile function compared to placebo (P<0.001 for each) [3]. The Physical Function Trial showed a modest but statistically significant improvement in walking distance. Bone density improved significantly in the Bone Trial.

These are the best-quality data available for older men with confirmed deficiency. They do not directly apply to men in their early 50s with testosterone in the low-normal range who are considering TRT for performance or mood optimization.

TRAVERSE: The Cardiovascular Safety Question

For years, cardiovascular safety was the central uncertainty in TRT prescribing. A 2010 trial published in the New England Journal of Medicine (N=209 older men with mobility limitations) was stopped early after a higher rate of cardiac adverse events in the testosterone arm [6]. That paper produced years of regulatory caution and an FDA safety communication in 2015 requiring all testosterone products to carry a label warning about cardiovascular risk [4].

TRAVERSE (Testosterone Replacement in Men with Hypogonadism and Cardiovascular Risk), published in the New England Journal of Medicine in 2023 (N=5,246), was designed specifically to settle this question [5]. Men with hypogonadism and either established cardiovascular disease or high cardiovascular risk were randomized to testosterone gel 1.62% or placebo and followed for a mean of 33 months. The primary composite cardiovascular outcome (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) occurred in 7.0% of the testosterone group vs. 7.3% of the placebo group, meeting the pre-specified non-inferiority margin [5].

TRAVERSE also found a higher rate of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone arm. Polycythemia occurred in 5.7% of testosterone-treated men vs. 0.8% of placebo [5]. These are real signals that require individualized risk discussion before prescribing.

What the Data Do Not Show

No trial to date has demonstrated that TRT reduces all-cause mortality. No trial has shown that testosterone started in eugonadal men (normal baseline levels) improves longevity or prevents cardiovascular disease. The Endocrine Society guideline states explicitly that it cannot recommend testosterone therapy for men who have age-related low testosterone without symptoms, or for men whose levels are in the normal range [2].

Celebrity Influence on TRT Demand: The Pattern Beyond Cohen

Andy Cohen is not the first public figure to normalize hormone therapy. The pattern follows a recognizable arc: a well-known man discloses TRT use, framing it in terms of vitality and wellbeing; search volume for TRT-related terms spikes; telehealth and direct-to-consumer testosterone companies report increased consultation requests; primary care physicians begin fielding more questions.

The Prescribing Surge Already on Record

A 2013 analysis in JAMA Internal Medicine examined prescription data from 2001 to 2011 across a large U.S. Managed-care database [7]. Testosterone prescriptions tripled over that decade, with the sharpest growth among men aged 40 to 64 who had no documented hypogonadism diagnosis. The authors noted that the growth correlated more strongly with direct-to-consumer advertising spend than with changes in diagnostic criteria.

A 2017 study in JAMA Internal Medicine (N=14,177 men) found that 25% of men who received a new testosterone prescription had no testosterone level measured in the prior year [8]. Another 40% had only one measurement, and many of those were afternoon draws rather than the required morning sample. This prescribing pattern, driven partly by patient demand generated by advertising and celebrity disclosure, represents a quality gap with real safety implications.

The Demand That Cohen's Disclosure Generates

Men who hear Cohen, a relatable, openly gay, 50-something New Yorker who is candid about health and aging, describe TRT as part of his routine are more likely to self-identify as candidates. The identification is not necessarily wrong. Symptomatic hypogonadism is underdiagnosed. A 2006 study in the International Journal of Clinical Practice estimated that only 12% of U.S. Men with symptomatic hypogonadism receive treatment [9].

The problem is the path. Men who present to telehealth platforms or direct-to-consumer clinics after a celebrity nudge are more likely to receive inadequate diagnostic workups, per the 2017 JAMA Internal Medicine data [8]. The answer is not discouraging the inquiry. It is channeling it into a rigorous diagnostic process.

What a Responsible Clinical Response Looks Like

When a patient presents citing Cohen or another celebrity, the clinical response should be:

1. Validate the inquiry. Symptomatic low testosterone is a real condition that warrants evaluation.
2. Order the correct workup. Two morning total testosterone measurements, free testosterone, LH, FSH, prolactin, hematocrit, PSA.
3. Apply the diagnostic threshold. Total testosterone <300 ng/dL on two occasions combined with symptoms meets the Endocrine Society definition of hypogonadism [2].
4. Discuss the TRAVERSE findings explicitly. Non-inferior cardiovascular risk overall, but real signals for atrial fibrillation, pulmonary embolism, and polycythemia that require individualized assessment [5].
5. Establish a monitoring plan before writing the first prescription.

TRT and Men's Health Beyond Testosterone: The Broader Hormone Picture

Fertility and Exogenous Testosterone

Testosterone therapy suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary-gonadal axis, reducing intratesticular testosterone and sperm production. Azoospermia or severe oligospermia develops in most men within 3 to 6 months of starting TRT. The American Society for Reproductive Medicine (ASRM) advises that men who may want biological children should consider alternatives including clomiphene citrate or human chorionic gonadotropin (hCG) instead of exogenous testosterone [10].

For men on TRT who wish to restore fertility, hCG at 1,500 to 3,000 IU three times weekly combined with FSH can restart spermatogenesis in the majority of cases, though recovery may take 6 to 18 months.

Estradiol Management

Aromatase converts testosterone to estradiol in adipose tissue. Men on TRT often experience rising estradiol, which can cause gynecomastia, fluid retention, and mood changes. Target estradiol on TRT is generally 20 to 40 pg/mL by sensitive assay (LC-MS/MS). Aromatase inhibitors such as anastrozole at 0.25 to 0.5 mg twice weekly are sometimes added, though the Endocrine Society cautions against routine use because suppression below 20 pg/mL negatively affects bone density and libido [2].

Sleep Apnea and TRT

Testosterone worsens obstructive sleep apnea in a dose-dependent manner. Men with untreated severe sleep apnea should not start TRT until the apnea is controlled. The TRAVERSE trial excluded men with untreated severe sleep apnea, meaning even its reassuring cardiovascular findings may not apply to that subgroup [5].

Talking to Your Doctor After Hearing About TRT From a Celebrity

The gap between celebrity narrative and clinical reality is not unbridgeable. Cohen's disclosure, like similar statements from other public figures, performs a useful function: it reduces stigma around men discussing hormonal health. The error is in assuming the narrative maps directly to a personal clinical situation.

Arrive at your appointment with specific symptoms and a timeline. "I have had reduced libido and fatigue for 18 months and I am not sleeping well" is actionable. "I want to feel like I did at 35" is a starting point for a conversation, not a prescription indication.

Ask for morning labs on two separate days. Ask for LH and FSH alongside total testosterone. Ask your clinician to walk you through the TRAVERSE findings so you understand the real cardiovascular data, not the version filtered through a podcast or a social media post.

If your levels confirm hypogonadism and your clinician recommends TRT, establish the monitoring schedule before your first dose. Hematocrit at 3 months is not optional. It catches the most common dose-related complication, polycythemia, before it becomes a clotting event.

The Endocrine Society's 2018 clinical guideline remains the most comprehensive framework available, and it states: "We suggest that clinicians should aim for testosterone levels in the mid-normal range, rather than the high-normal range, to minimize adverse effects." [2] That instruction applies regardless of what any celebrity reports about his personal energy levels.